Hormonal
BPC-157 accelerates tissue repair (tendons, muscles, ligaments, GI mucosa) by stimulating angiogenesis and modulating inflammation, though it lacks FDA approval and robust human clinical trials.
BPC-157 is a peptide studied for its ability to speed up the healing of tendons, muscles, and gut lining. While animal studies show promising results for tissue repair, it is not yet approved by the FDA for human use. It is sometimes used off-label in sports medicine, but robust human clinical trials are still needed to confirm its safety and efficacy.
Its mechanism is multimodal: it stimulates angiogenesis (via increased VEGF and VEGFR2), modulates nitric oxide synthesis, accelerates granulation formation and collagen deposition, and reduces local inflammation [27,61]. Main targets: injured tissues—tendons, muscles, ligaments, bone, peripheral nerves, and gastrointestinal mucosa—according to preclinical evidence [11,62].
Why this rating
Based primarily on preclinical (animal) evidence and limited human anecdotal/compassionate use; no large-scale RCTs cited.
Source
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Guilherme Renke et al. · International Journal of Molecular Sciences · 2026
DOI 10.3390/ijms27093890
More from this paper
- Triple-agonist GLP-1/GIP/Glucagon analogs (e.g., retatrutide) produce superior weight loss compared to dual or single agonists by synergistically activating multiple satiety and energy expenditure pathways.Good
- Topical cosmetic peptides (e.g., GHK-Cu, Matrixyl, Argirelin) reduce wrinkles and improve skin firmness with excellent safety profiles, though effects are modest and require consistent long-term use.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →